GlassScriptPhysician profile
Mohamed Ismaile Abdalla
NPI 1528413598
$1,902.18
in general payments reported to CMS, 2019-2025
22 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $17.97 · 2022: $159 · 2023: $423 · 2024: $499 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $433.98 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $253.22 | 2023-2025 | Fasenra, Breztri, Tezspire |
| Abiomed | $146.67 | 2022 | |
| Abbvie INC. | $137.42 | 2023-2025 | Avycaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.06 | 2019-2025 | Ofev |
| Insmed, INC. | $98.06 | 2019-2025 | Arikayce |
| Boston Scientific Corporation | $92.11 | 2023-2025 | Watchman Flx |
| Mallinckrodt Hospital Products INC. | $85.75 | 2024-2025 | Acthar |
| Tactile Systems Technology INC | $81.83 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Electromed, INC. | $79.09 | 2023-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $77.40 | 2019-2022 | |
| United Therapeutics Corporation | $54.22 | 2024-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $42.70 | 2025 | Glassia |
| Philips North America LLC | $33.22 | 2024 | (2383) Sleepundivided, (Ak6) Vest Therapy |
| Grifols USA, LLC | $28.93 | 2025 | Prolastin-C Liquid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25.49 | 2024 | |
| Verona Pharma, INC. | $24.96 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $24.52 | 2023 | Inspire |
| Amgen INC. | $21.40 | 2023 | Tezspire |
| Axsome Therapeutics, INC. | $17.15 | 2024 | Sunosi |
| Baxter Healthcare | $17.01 | 2024 | Hillrom - Monarch Airway Clearance System |
| Regeneron Healthcare Solutions, INC. | $16.99 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.